AbbVie Inc ABBV
News
AbbVie to Host Third-Quarter 2024 Earnings Conference Call
AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell Lung Cancer
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
AbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's Study
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns
AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
AbbVie Declares Quarterly Dividend
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
AbbVie, Genmab Lymphoma Treatment Gets European Commission Marketing Authorization
European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Medicare's negotiated drug prices will save taxpayers $6 billion in first year, White House says